CytoCell

ogt

A Sysmex Group Company

Pathology Probes for Glioma



Features

- Improve confidence in result interpretation with high intensity signals and minimal background
- Maximise signal quality when probes are used in conjunction with our Tissue Pretreatment Kit
- Enhance detection and scoring accuracy with robust, easy-to-analyse probes
- Save time and minimise mixing errors with easy-to-use, pre-mixed probes
- Optimise stock levels and minimise wastage with flexible pack sizes to meet your needs

1p36/1q25 and 19q13/19p13 Deletion Probe Kit

Cat. No. **LPS 047-S** (5 tests) | Cat. No. **LPS 047** (10 tests)

Deletions of the 1p36.32 region including the TP73 (*tumor protein p73*) gene and deletions of the 19q13.33 region including the GLTSCR1 (*BICRA, BRD4 interacting chromatin remodeling complex associated protein*) and GLTSCR2 (*NOP53, NOP53 ribosome biogenesis factor*) genes are frequently reported in cases of glial tumours.

Astrocytomas and oligodendrogliomas are the most common gliomas that arise from glial cells. They make up about 40% of all CNS tumours[1] and more than 60% of primary brain cancers[2].

Concurrent losses, 'co-deletion', of the 1p36.32 and 19q13.33 regions are reported in approximately 80% of oligodendrogliomas, two-thirds of anaplastic oligodendrogliomas, as well as subsets of oligoastrocytomas and anaplastic oligoastrocytomas[3,4]; the majority of these losses have been shown to be mediated by the presence of an unbalanced t(1;19) (q10;p10) translocation. The presence of a 1p and 19q co-deletion is a strong prognostic factor in these diseases, where it is associated with improved prognosis and responsiveness to therapy[5].

1p and 19q co-deletion has also been shown to occur in a subset of extraventricular neurocytomas, and may be associated with aggressive histology in these tumours[6].



CMP S064 v001



CMP-S069 v001

References

1. Globocan Cbtrus (2004). Central Brain Tumor Registry of the United States.
2. Thompson L. Ear Nose Throat J. 2006 Feb;85(2):74.
3. Vogazianou AP, *et al*. Neuro Oncol. 2010 Jul;12(7):664-78.
4. Bromberg JEC, *et al*. Oncol. 2009. 14:155-163.
5. Jenkins RB, *et al*. Cancer Res 2006;66(20):9852-61.
6. Rodriguez FJ, *et al*. Brain Pathol 2009;19(4):623-9.

Tissue Pretreatment Kit

Cat. No. **LPS 100***

Our tissue pretreatment kit is designed to prepare slides for FISH analysis on formalin-fixed paraffin embedded (FFPE) tissue.

Our extensive Pathology FISH range has been optimised to produce excellent visual results with our ready-to-use Tissue Pretreatment Kit.

With ease-of-use and convenience in mind, our simple two stage FFPE slide preparation protocol employs ready-to-use reagents, which have been optimised to increase the permeabilisation of cell membranes and facilitate penetration of the desired FISH DNA probe.

* This product is provided under an agreement between Life Technologies Corporation and Cytocell Ltd and is available for human diagnostics or life science research use only.

The OGT Partnership

Behind every sample is a life that can be improved through the right care decisions.
The OGT partnership approach is key to providing the highest level of service, working closely with you to understand your unique challenges, customising our approach to meet your exact needs. Choose CytoCell® probes for your FISH analysis; our effective, accurate and simple to use products help clinical decision makers to reach the right decisions for each patient.

CytoCell

Pathology Probes for Glioma

Ordering information

UK +44 (0) 1223 294048
contact@ogt.com
ogt.com

Glioma probes

Probe Name	No. Tests	Cat. No.§
1p36/1q25 and 19q13/19p13 Deletion Probe Kit	5 or 10	LPS 047
Pretreatment Kit*	N/A	LPS 100

* This product is provided under an agreement between Life Technologies Corporation and Cytocell Ltd and is available for human diagnostics or life science research use only.

Related products

A small selection of our extensive portfolio of CytoCell FISH probes designed for use on FFPE sections, many of which are applicable to brain tumour and other cancer diagnostics, is shown below:

Probe Name	No. Tests	Cat. No.§
EGFR Amplification	5 or 10	LPS 003
MDM2 Amplification	5 or 10	LPS 016
N-MYC (MYCN) Amplification	5 or 10	LPS 009

§ For 5 test kit add –S to the catalogue number , e.g,: LPS ###-S.

A Sysmex Group Company

What binds us, makes us.

Cytocell Ltd., Oxford Gene Technology, 418 Cambridge Science Park, Milton Road, Cambridge, CB4 0PZ, UK